Ovid Therapeutics (OVID) Receivables - Other (2016 - 2022)

Ovid Therapeutics (OVID) has reported Receivables - Other for 6 consecutive years, with $750000.0 the latest figure, recorded in Q1 2022.

• For the quarter ending Q1 2022, Receivables - Other fell 26.74% year-over-year to $750000.0; the trailing twelve-month figure through Mar 2022 stood at $750000.0 (down 26.74% YoY), and the FY2020 full-year result was $141763.0, down 87.47% from the prior year.
• Receivables - Other slipped to $750000.0 in Q1 2022 per OVID's latest filing, from $1.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $1.6 million in Q2 2019 and bottomed at $141763.0 in Q4 2020.
• Historically, Receivables - Other has averaged $808531.9 across 5 years, with a median of $699497.5 in 2020.
• The sharpest annual moves came in 2020 and 2021: Receivables - Other plunged 87.47% in 2020, then jumped 173.56% in 2021.
• Over 5 years, Receivables - Other stood at $600104.0 in 2018, then soared by 88.49% to $1.1 million in 2019, then slumped by 87.47% to $141763.0 in 2020, then surged by 622.18% to $1.0 million in 2021, then fell by 26.74% to $750000.0 in 2022.
• According to Business Quant data, Receivables - Other over the past three periods registered $750000.0, $1.0 million, and $141763.0 for Q1 2022, Q1 2021, and Q4 2020 respectively.